natgillin/translations-raw huggingface dataset:
PBA er en følge af neurologiske sygdomme i hjernen eller hjernetraumer og er kendetegnet ved episoder med involuntære, ukontrollerbare følelsesudbrud med latter og/eller gråd uden sammenhæng eller ude af proportioner med patientens emotionelle tilstand eller sindsstemning. 
PBA is a consequence of neurological diseases affecting the brain, or brain, injury and is defined by episodes of involuntary, uncontrollable emotional expressions of laughing and/or crying that are incongruous or disproportionate to the patient's emotional state or mood.
Ualmindelige bivirkninger: (forekommer hos indtil 1 ud af 100 behandlede): 
Uncommon side effects (may affect up to 1 in 100 people)
Kapsler, hårde. 
Hard capsule
Patienterne skal advares om potentialet for CNS-relaterede virkninger såsom somnolens, svimmelhed, synkope og nedsat syn (se pkt. 
Patients should be warned about the potential for CNS-related effects like somnolence, dizziness and syncope or impaired vision (see section 4.8), and advised not to drive or operate machinery if these symptoms occur.
Andre bivirkninger er ataksi, nystagmus, dystoni, sløret syn og ændrede muskelreflekser. 
Other adverse reactions include ataxia, nystagmus, dystonia, blurred vision, and changes in muscle reflexes.
Ved inadækvat klinisk respons med NUEDEXTA, 15 mg/9 mg, ordineres NUEDEXTA, 23 mg/9 mg, to gange dagligt, én om morgenen og én om aftenen med 12-timers mellemrum. 
If the clinical response with NUEDEXTA 15 mg/9 mg is inadequate, NUEDEXTA 23 mg/9 mg should be prescribed, taken two times per day, one in the morning and one in the evening, 12 hours apart.
Egnede patienter fik fastlagt diagnosen PBA ved episoder med involuntære, ukontrollerbare følelsesudbrud med latter og/eller gråd uden sammenhæng eller ude af proportioner med patientens emotionelle tilstand eller sindsstemning. 
Eligible patients had a diagnosis of PBA defined by episodes of involuntary, uncontrollable emotional expressions of laughing and/or crying that are incongruous or disproportionate to their emotional state or mood.
NUEDEXTA indeholder lactose. 
NUEDEXTA contains lactose.
Rødbrune gelatinekapsler, størrelse 1, med påskriften “DMQ/20-10” med hvid trykfarve på kapslen. 
Brick red gelatin capsule, size 1, with “DMQ / 20-10” printed in white ink on the capsule.
Hos patienter med svært nedsat leverfunktion (Child-Pugh C) eller svært nedsat nyrefunktion (kreatininclearance < 30 ml/min/1,73 m2) bør de potentielle risici ved lægemidlets anvendelse afvejes mod det medicinske behov (se pkt. 
In patients with severe hepatic impairment (Child-Pugh C) or severe renal impairment (Creatinine Clearance < 30 mL/min/1.73m
NUEDEXTA kan forårsage svimmelhed (se pkt. 
NUEDEXTA may cause dizziness (see section 4.8).
• du efter at have taget dette lægemiddel får symptomer på en allergisk reaktion såsom hævelse i halsen eller af tungen, vejrtrækningsbesvær, svimmelhed, feber, udslæt eller nældefeber 
• you develop symptoms of an allergic reaction such as swelling of the throat or tongue, difficulty breathing, dizziness, fever, rash, or hives after taking this medicine.
PBA er en neurologisk sygdom kendetegnet af ufrivillige og ukontrollerbare episoder med latter og gråd, som ikke svarer til følelser eller sindsstemning hos den pågældende. 
PBA is a neurological condition characterized by involuntary and uncontrollable episodes of laughing and/or crying, which don't match your emotional state or mood.
Samtidig brug af NUEDEXTA og tricykliske antidepressiva frarådes på grund af den farmakodynamiske og farmakokinetiske interaktion og den forhøjede risiko for serotoninsyndrom (se pkt. 
Given the pharmacodynamic and pharmacokinetic interactions, concomitant use of NUEDEXTA and TCAs is not recommended due to the elevated risk of serotonin syndrome (see section 4.5).
Hos patienter med let til moderat nedsat leverfunktion kræves derfor ingen dosisjustering, men øget overvågning for bivirkninger bør overvejes. 
Therefore, dosage adjustment is not required in patients with mild and moderate hepatic impairment, although additional monitoring for adverse reactions should be considered in patients with moderate hepatic impairment.
Dextromethorphan/kinidin i denne dosis øgede steady state-koncentrationen af desipramin til ca. den 8-dobbelte. 
The combination dose of dextromethorphan/quinidine increased steady state desipramine levels approximately 8-fold.
Sjælden (forekommer hos indtil 1 ud af 1 000 behandlede): 
Rare (may affect up to 1 in 1,000 people)
Sådan skal du tage NUEDEXTA 
How to take NUEDEXTA
• perikum (et naturlægemiddel, der anvendes til behandling af depression) 
• St John's wort, a herbal medicine used to treat depression
• unormal afføring, fordøjelsesbesvær, irritation af maveslimhinden (gastritis), følelsesløshed og abnorm følesans i munden, smerter fra endetarmen, mundtørhed 
• abnormal faeces, indigestion, inflammation of the lining of the stomach (gastritis), numbness and abnormal sensation in the mouth, rectal pain, dry tongue
• lægemidler mod hiv-smitte og aids såsom atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, 
• medicines used to treat HIV infection and AIDS, such as atazanavir, indinavir, nelfinavir,
Paroxetin (CYP2D6-hæmmer og -substrat) 
Paroxetine (CYP2D6 inhibitor and substrate)
Ubehag i brystet, brystsmerter, kulderystelser, varmefølelse, gangforstyrrelser, influenzalignende sygdom, pyreksi, nedsat oxygenmætning 
Chest discomfort, Chest pain, Chills, Feeling hot, Gait disturbance, Influenza like illness, Pyrexia, Oxygen
Desipramin (CYP2D6-substrat) 
Desipramine (CYP2D6 substrate)
• svimmelhed, hovedpine, døsighed 
• dizziness, headache, drowsiness
Særlig risiko foreligger ved behandling med lægemidler, som både forlænger QT-intervallet og primært metaboliseres af CYP2D6 (se nedenfor). 
Concomitant medicinal products that both prolong the QT interval and are primarily metabolised by CYP2D6 (see below) are of particular potential concern.
Samtidig anvendelse af CYP2D6-substrater/-inhibitorer. 
Concomitant use of CYP2D6 substrates/inhibitors
Når du får to kapsler inden for 24 timer, skal der gå ca. 12 timer mellem hver. 
When taking two capsules within 24 hours, you should leave about 12 hours between doses.
Hypertrofi og dysfunktion af venstre ventrikel forekommer oftere hos patienter med kronisk hypertension, kendt koronararteriesygdom eller anamnese med apopleksi. 
LVH and LVD are more likely to be present in patients with chronic hypertension, known coronary artery disease or history of stroke.
I en undersøgelse, hvor der blev givet en kombineret dosis af dextromethorphan 23 mg/kinidin 26 mg to gange dagligt til 12 personer med let (kreatininclearance 50-80 ml/min) eller moderat (kreatininclearance 30-50 ml/min) nyrefunktionsnedsættelse (6 af hver), sås ringe forskel i farmakokinetikken af kinidin og dextromethorphan i forhold til 9 raske sammenligningspersoner (matchede i køn, alder og vægt). 
In a study of a combination dose of dextromethorphan 23 mg / quinidine 26 mg twice daily in 12 subjects with mild (CLCR 50-80 mL/min) or moderate (CLCR 30-50 mL/min) renal impairment (6 each) compared to 9 healthy subjects (matched in gender, age, and weight range to impaired subjects), subjects showed little difference in quinidine or dextromethorphan pharmacokinetics compared to healthy subjects.
• ubehag i brystet, brystsmerter, kulderystelser, varmefølelse, gangforstyrrelser, influenzalignende sygdom, feber, nedsat iltmætning i blodet 
• chest discomfort, chest pain, chills, feeling hot, gait disturbance (difficulty walking), flu-like illness, fever, decreased oxygen levels in the blood
Ved myasthenia gravis og andre sygdomme, der kan forværres ved antikolinerg påvirkning, bør den kliniske tilstand overvåges. 
Patients should be monitored for worsening clinical condition in myasthenia gravis and other conditions that may be adversely affected by anticholinergic effects.
• hvis du er i behandling med MAO-hæmmere (lægemidler mod depression), f.eks. phenelzin eller moclobemid, eller har været det inden for de seneste 14 dage. 
• if you are taking, or have taken during the last two weeks, certain medicines for depression called monoamine oxidase inhibitors (MAOIs), such as phenelzine and moclobemide.
Bivirkningerne ved overdosering med dextromethorphan er kvalme, opkastning, stupor, koma, respirationsdepression, krampeanfald, takykardi, hyperexcitabilitet og toksisk psykose. 
Adverse reactions of dextromethorphan overdose include nausea, vomiting, stupor, coma, respiratory depression, seizures, tachycardia, hyperexcitability, and toxic psychosis.
Flaske af HD-polyethylen (HDPE) med børnesikret låg af polypropylen. 
High density polyethylene (HDPE) bottle with a child resistant polypropylene cap. Each bottle is packed in a carton.
Lægemiddelinteraktioner med desipramin og paroxetin har været genstand for kontrollerede kliniske undersøgelser med kombinationen af dextromethorphan og kinidin i en højere dosis (dextromethorphan 23 mg/kinidin 26 mg) end i dette lægemiddel. 
Drug interactions with desipramine and paroxetine have been studied in controlled clinical trials with a higher dose combination of dextromethorphan/quinidine (dextromethorphan 23 mg/ quinidine 26 mg) than in this medicinal product; study results are described below.
• ikke almindelig (≥1/1 000 til <1/100) 
• uncommon (≥1/1,000 to <1/100)
besvimelse (synkope), faldtendens 
(syncope), fall
I en undersøgelse, hvor der blev givet en kombineret dosis af dextromethorphan 23 mg/kinidin 26 mg to gange dagligt til 12 personer med let eller moderat nedsat leverfunktion (i henhold til Child-Pughmetoden; 6 af hver), var AUC, Cmax og clearance af dextromethorphan den samme som hos 9 raske sammenligningspersoner (matchede i køn, alder og vægt). 
In a study of a combination dose of dextromethorphan 23 mg / quinidine 26 mg twice daily in 12 subjects with mild or moderate hepatic impairment (as indicated by the Child-Pugh method; 6 each) compared to 9 healthy subjects (matched in gender, age, and weight range to impaired subjects), subjects with moderate hepatic impairment showed similar dextromethorphan AUC and Cmax and clearance compared to healthy subjects.
Brug af anden medicin sammen med NUEDEXTA Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin, har gjort det for nylig eller påtænker at gøre det. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Erytem, hyperhidrose, facial hypæstesi, erytem, nattesved 
Erythema, Hyperhidrosis, Hypoaesthesia facial, Night sweats
For pro-drugs, hvis virkning medieres af metabolitter frembragt af CYP2D6, kan NUEDEXTA væsentligt forringe virkningen ved at hæmme CYP2D6 og mindske dannelsen af den aktive metabolit. 
In the case of pro-drugs whose actions are mediated by the CYP2D6-produced metabolites (for example, codeine and hydrocodone, whose analgesic and antitussive effects appear to be mediated by morphine and hydromorphone, respectively), efficacy may be substantially reduced by NUEDEXTA due to inhibition of CYP2D6 and hence impaired formation of the active metabolite.
Der blev udført to yderligere fase III-undersøgelser med en højere dosering: dextromethorphan 23 mg/kinidin 26 mg. 
Two additional phase III studies were conducted using a higher dose combination of dextromethorphan 23 mg/quinidine 26 mg.
Desuden kan det medføre opkastning, diarré, ringen for ørerne, høretab ved høje toner, svimmelhed, sløret syn, dobbeltsyn, øget lysfølsomhed af øjnene, hovedpine, omtågethed og delirium (karakteriseret ved svækket opmærksomhed, dårlig hukommelse, desorientering og talevanskeligheder). 
Symptoms of quinidine overdose include irregular heartbeat and low blood pressure, and may also include vomiting, diarrhoea, ringing in the ears, high-frequency hearing loss, vertigo, blurred vision, double vision, increased sensitivity of the eyes to light, headache, confusion, and delirium (characterised by loss of attention, poor memory, disorientation, impaired speech).
Diplopi, sløret syn 
Diplopia, Vision blurred
Yderligere oplysninger herom fremgår af indlægssedlen. 
See leaflet for further information.
Patienter med nedsat nyre- eller leverfunktion 
Patients with renal and hepatic impairment
Samtidig anvendelse af MAO-hæmmere er kontraindiceret (se pkt. 
Combination with MAOIs is contraindicated (see section 4.3).
• lægemidler, der anvendes til behandling af bakterielle infektioner, herunder tuberkulose, og som indeholder clarithromycin, telithromycin, erythromycin eller rifampicin 
• medicines used to treat bacterial infections, including tuberculosis, containing clarithromycin,
Hud og subkutane væv Ikke almindelig Udslæt 
Skin and subcutaneous tissue disorders
Risikoen øges ved overdosering, navnlig ved indtagelse sammen med andre serotonerge lægemidler, SSRI eller tricykliske antidepressiva. 
Dextromethorphan may increase the risk of serotonin syndrome, and this risk is increased by overdose, particularly if taken with other serotonergic agents, SSRIs or tricyclic antidepressants.
Hvis du har taget for mange NUEDEXTA tabletter Kontakt straks lægen, hvis du har taget for mange kapsler. 
If you have taken more capsules than you should, speak to your doctor immediately.
Der er derfor ikke behov for dosisjustering for patienter med let til moderat nedsat nyrefunktion. 
Dose adjustment is therefore not required in mild or moderate renal impairment.
Symptomerne på serotoninsyndrom er uro, for højt blodtryk, rastløshed, muskelspasmer, sitren og rysten, forhøjet temperatur, svedtendens, kulderystelser og rysten. 
Symptoms of serotonin syndrome include agitation, high blood pressure, restlessness, muscle spasms and twitching, high body temperature, excessive sweating, shivering, and tremor.
Dysgeusi, hypersomni, muskelspasticitet, synkope, faldtendens 
Uncommon Dysgeusia, Hypersomnia, Muscle spasticity, Syncope, Fall
Metabolisme og ernæring Ikke almindelig Nedsat appetit 
Uncommon Decreased appetite
• NUEDEXTA, 15 mg/9 mg, er rødbrune gelatinekapsler, størrelse 1, med påskriften “DMQ/20 
• NUEDEXTA 15 mg/9 mg is a brick red gelatin capsule, size 1, with “DMQ / 20-10” printed in white ink on the capsule.
NUEDEXTA, 23 mg/9 mg 
INFORMATION IN BRAILLE NUEDEXTA 23 mg/9 mg
Afgørende for diagnosen er tilstedeværelsen af en underliggende neurologisk sygdom, der vides at medføre PBA, og bekræftelse af, at episoderne med emotionelle udbrud er uden sammenhæng eller ude af proportioner med patientens emotionelle tilstand eller sindsstemning. 
Before treatment with Nuedexta is initiated patients must be fully evaluated to confirm the diagnosis of PBA. Central to the diagnosis are the presence of an underlying neurological condition known to cause PBA, and confirmation that the episodes of emotional expression do not reflect the patient's emotional state or mood.
Dette kan påvirke sikkerhed og/eller virkning af lægemidler, der anvendes sammen med NUEDEXTA og metaboliseres af CYP2D6 (se pkt. 
Because of this effect on CYP2D6, accumulation of parent drug substances and/or failure of active metabolite formation may affect the safety and/or the efficacy of medicinal products used concomitantly with NUEDEXTA that are metabolised by CYP2D6 (see section 4.5).
NUEDEXTA, 15 mg/9 mg 
INFORMATION IN BRAILLE NUEDEXTA 15 mg/9 mg
NUEDEXTA, kapsler, hårde, 15 mg/9 mg NUEDEXTA, kapsler, hårde, 23 mg/9 mg dextromethorphan/kinidin 
NUEDEXTA 15 mg/9 mg hard capsules NUEDEXTA 23 mg/9 mg hard capsules dextromethorphan / quinidine
• træthed 
• fatigue
• meget almindelig (>1/10) 
• very common (≥1/10)
Både dextromethorphan og memantin er antagonister til N-methyl-D-aspartat- (NMDA-) receptoren. 
Both dextromethorphan and memantine are antagonists of the N-methyl-D-aspartate (NMDA) receptor which could theoretically result in an additive effect at NMDA receptors and potentially an increased incidence of adverse reactions.
Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
Check with your doctor or pharmacist if you are not sure.
• visse lægemidler mod depression, der kaldes monoaminoxidasehæmmere (MAO-hæmmere), 
• certain medicines for depression, called monoamine oxidase inhibitors (MAOIs- for example phenelzine and moklobemide).
Abdominalsmerter, konstipation, mundtørhed, flatulens, ubehag i maven, opkastning 
Common Diarrhoea, Nausea Abdominal pain, Constipation, Dry mouth, Flatulence, Stomach discomfort, Vomiting
Muskelstivhed, myalgi, nakkesmerter, ekstremitetssmerter 
ritonavir, saquinavir, amprenavir, fosamprenavir
HYLSTER TIL BLISTER (13 kapsler, hårde) - NUEDEXTA, kapsler, 15 mg/9 mg 
BLISTER SLEEVE (13 hard capsules) - NUEDEXTA 15 mg/9 mg capsules
• lægemidler, mod forskellige hjertesygdomme, således diltiazem, verapamil, digoxin, flecainid og betablokkere (såsom metoprolol) 
• medicines used to treat various heart conditions, such as diltiazem, verapamil, digoxin,
• tænderskæren (bruksisme), omtågethed, nedtrykthed, depression, desorientering (f.eks. vanskelighed ved at opfatte tidspunkt og retning eller genkende personer og steder), opvågnen tidligt om morgenen, nedsat følelsesudtryk (affektaffladning), sansebedrag (hallucinationer), pludselige indskydelser (impulsiv adfærd), ligegyldighed, søvnløshed (insomni), rastløshed, søvnforstyrrelser 
• teeth grinding (bruxism), confusion, depressed mood, depression, disorientation (e.g. difficulty sensing time, direction, and recognition of people and places), early morning awakening,
NUEDEXTA, kapsler, hårde, 15 mg/9 mg dextromethorphan/kinidin 
NUEDEXTA 15 mg/9 mg hard capsules dextromethorphan / quinidine
NUEDEXTA kan medføre svimmelhed. 
Driving and using machines NUEDEXTA may cause dizziness.
NUEDEXTA, kapsler, hårde, 23 mg/9 mg dextromethorphan/kinidin 
NUEDEXTA 23 mg/9 mg hard capsules dextromethorphan / quinidine
I tilstedeværelse af en fast dosis kinidin således som den, der er indeholdt i NUEDEXTA, er plasmakoncentrationerne af dextromethorphan og dextrorphan proportionale med dextromethorphandosis. 
Plasma concentrations of dextromethorphan and dextrorphan are proportional to dextromethorphan dose in the presence of a fixed dose of quinidine such as that contained in NUEDEXTA.
Andre tilknyttede symptomer er udslæt, bronkospasme, lymfadenopati, hæmolytisk anæmi, vaskulitis, uveitis, angioødem, agranulocytose, siccasyndrom, myalgi, forhøjet serumkoncentration af skeletmuskelenzymer og pneumonitis. 
Quinidine at higher doses has also been associated with a lupus-like syndrome involving polyarthritis, sometimes with a positive antinuclear antibody test. Other associations include rash, bronchospasm, lymphadenopathy, haemolytic anaemia, vasculitis, uveitis, angioedema, agranulocytosis, the sicca syndrome, myalgia, elevation in serum levels of skeletal-muscle enzymes, and pneumonitis.
YDERKARTON - NUEDEXTA, kapsler, hårde, 15 mg/9 mg INDEHOLDER 13 KAPSLER 
OUTER CARTON - NUEDEXTA 15 mg/9 mg capsules: PACK OF 13 CAPSULES
Symptomerne på overdosering med dextromethorphan er kvalme, opkastning, sløvhed, bevidstløshed, nedsat vejrtrækning, krampeanfald, øget hjerterytme, irritabilitet og psykose som følge af giftpåvirkning. 
Symptoms of dextromethorphan overdose include nausea, vomiting, stupor, coma, respiratory depression, seizures, increased heart rate, hyperexcitability, and toxic psychosis.
Hver kapsel NUEDEXTA, 23 mg/9 mg, indeholder dextromethorphanhydrobromidmonohydrat svarende til 23,11 mg dextromethorphan og kinidinsulfatdihydrat svarende til 8,69 mg kinidin. 
Each NUEDEXTA 23 mg/9 mg capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 23.11 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Hver kapsel NUEDEXTA, 15 mg/9 mg, indeholder dextromethorphanhydrobromidmonohydrat svarende til 15,41 mg dextromethorphan og kinidinsulfatdihydrat svarende til 8,69 mg kinidin. 
Each NUEDEXTA 15 mg/9 mg capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Særlige patientkategorier 
Elderly patients
FLASKEKARTON (60 kapsler, hårde) - NUEDEXTA, kapsler, 23 mg/9 mg 
BOTTLE CARTON (60 hard capsules) - NUEDEXTA 23 mg/9 mg capsules
Samtidig anvendelse af NUEDEXTA og tricykliske antidepressiva frarådes (se pkt. 
Concomitant use of NUEDEXTA and TCAs is not recommended (see section 4.4).
• mavesmerter, forstoppelse, mundtørhed, tarmluft (flatulens), ubehag i maven, opkastning 
• abdominal pain, constipation, dry mouth, wind (flatulence), stomach discomfort, vomiting
• stofmisbrug 
• Drug misuse and abuse
Den første var en 4-ugers undersøgelse hos patienter med PBA med underliggende ALS, mens den anden var en 12-ugers undersøgelse hos patienter med underliggende MS. I begge undersøgelser resulterede kombinationen dextromethorphan/kinidin i statistisk signifikant reduktion i det primære mål for udfald, CNS-LS, og i det sekundære mål for udfald, “antal episoder med latter og gråd”. 
The first was a 4-week study in PBA subjects with underlying ALS, and the second was a 12-week study in subjects with underlying MS.
Før og efter dosering bør der tages EKG med henblik på virkningen af kombinationen på QTc-intervallet. 
The effect of the combination on the patient's QTc interval should be evaluated with pre- and post-dose ECGs.
Det skal du vide, før du begynder at tage NUEDEXTA Sådan skal du tage NUEDEXTA Bivirkninger 
What NUEDEXTA is and what it is used for What you need to know before you take NUEDEXTA How to take NUEDEXTA
Hver kapsel indeholder dextromethorphanhydrobromidmonohydrat svarende til 23,11 mg dextromethorphan og kinidinsulfatdihydrat svarende til 8,69 mg kinidin. 
Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 23.11 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Hold op med at tage kapslerne og kontakt straks lægen, hvis du får nogen af ovenstående symptomer. 
If any of the above occur, stop taking the capsules and tell your doctor immediately
Hver kapsel indeholder dextromethorphanhydrobromidmonohydrat svarende til 15,41 mg dextromethorphan og kinidinsulfatdihydrat svarende til 8,69 mg kinidin. 
Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
I en lægemiddelinteraktionsundersøgelse blev en højere dosis af kombinationen (dextromethorphan 23 mg/kinidin 26 mg) anvendt sammen med memantin, 20 mg dagligt. 
A drug-drug interaction study was conducted between a higher combination dose of dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) and memantine 20 mg/day.
Der er udført en lægemiddelinteraktionsundersøgelse med desipramin, 25 mg, og en højere dosis af kombinationen dextromethorphan/kinidin (dextromethorphan 23 mg/kinidin 26 mg). 
A drug-drug interaction study was conducted between a higher combination dose of dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) and desipramine 25 mg.
FLASKEKARTON (60 kapsler, hårde) - NUEDEXTA, kapsler, 15 mg/9 mg 
BOTTLE CARTON (60 hard capsules) - NUEDEXTA 15 mg/9 mg capsules
• NUEDEXTA, 23 mg/9 mg, er rødbrune gelatinekapsler, størrelse 1, med påskriften “DMQ/30 
• NUEDEXTA 23 mg/9 mg is a brick red gelatin capsule, size 1, with “DMQ / 30-10” printed in white ink on the capsule and three white bands around the circumference.
I en lægemiddelinteraktionsundersøgelse blev paroxetin i steady state suppleret med kombinationen dextromethorphan/kinidin i en højere dosis (dextromethorphan 23 mg/kinidin 26 mg). 
In a drug-drug interaction study, a higher combination dose of dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) was added to paroxetine at steady state.
• muskeltrækninger 
Printing ink
Ekstra overvågning af bivirkninger hos sådanne patienter tilrådes. 
However, as there was a trend toward increased incidence of adverse reactions in patients with moderate hepatic impairment, additional monitoring of adverse reactions is advised in these patients.
Det vides ikke, om dextromethorphan udskilles i modermælk. 
Quinidine is excreted in human milk and it is unknown whether dextromethorphan is excreted in human milk.